PE20150218A1 - Nuevos derivados fosfatos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen - Google Patents

Nuevos derivados fosfatos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen

Info

Publication number
PE20150218A1
PE20150218A1 PE2014001093A PE2014001093A PE20150218A1 PE 20150218 A1 PE20150218 A1 PE 20150218A1 PE 2014001093 A PE2014001093 A PE 2014001093A PE 2014001093 A PE2014001093 A PE 2014001093A PE 20150218 A1 PE20150218 A1 PE 20150218A1
Authority
PE
Peru
Prior art keywords
carbonyl
contain
pharmaceutical compositions
alkyl
preparation procedure
Prior art date
Application number
PE2014001093A
Other languages
English (en)
Inventor
Tiran Arnaud Le
Diguarher Thierry Le
Jer& ;Me-Beno& ;T Starck
Jean-Michel Henlin
Anne-Fran& ;Oise Guillouzic
Nanteuil Guillaume De
Olivier Geneste
James Edward Paul Davidson
James Brooke Murray
I-Jen Chen
Original Assignee
Servier Lab
Vernalis Randd Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50288170&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20150218(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab, Vernalis Randd Ltd filed Critical Servier Lab
Publication of PE20150218A1 publication Critical patent/PE20150218A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/10X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/08Esters of oxyacids of phosphorus
    • C07F9/09Esters of phosphoric acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/10X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092Details
    • A61N2005/1098Enhancing the effect of the particle by an injected agent or implanted device

Abstract

SE REFIERE A DERIVADOS DE FOSFATOS DE FORMULA (I) DONDE X E Y SON CADA UNO C O N; A1 Y A2 FORMAN JUNTO CON LOS ATOMOS A LOS QUE ESTAN UNIDOS UN HETEROCICLO DE 5 A 7 ESLABONES O A1 Y A2 SON CADA UNO H, ALQUILO(C1-C6), ENTRE OTROS; T ES H, ALQUILO(C1-C6), ENTRE OTROS; R3 ES ALQUILO(C1-C6), CICLOALQUILO, ARILO, ENTRE OTROS; R4 ES ARILO, HETEROARILO, ENTRE OTROS; R5 ES H, HALOGENO, ENTRE OTROS; Ra, Rb, Rc Y Rd SON CADA UNO HALOGENO, ALCOXI(C1-C6), HIDROXI, TRIFLUOROMETOXI, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 4-[{[3-(6-{[(3S)-3-(MORFOLIN-4-ILMETIL)-3,4-DIHIDROISOQUINOLIN-2(1H)-IL]CARBONIL}-1,3-BENZODIOXOL-5-IL)-5,6,7,8-TETRAHIDROINDOLIZIN-1-IL]CARBONIL}(FENIL)AMINO]FENIL FOSFATO DE DISODIO; 4-[{[5-(5-CLORO-2-{[(3S)-3-(MORFOLIN-4-ILMETIL)-3,4-DIHIDROISOQUINOLIN-2(1H)-IL]CARBONIL}FENIL)-1,2-DIMETIL-1H-PIRROL-3-IL]CARBONIL}(PIRIDIN-4-IL)AMINO]FENIL FOSFATO DE DISODIO; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON UTILES EN EL TRATAMIENTO DE CANCER, ENFERMEDADES AUTOINMUNES
PE2014001093A 2013-07-23 2014-07-10 Nuevos derivados fosfatos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen PE20150218A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1357259A FR3008979B1 (fr) 2013-07-23 2013-07-23 Nouveaux derives phosphates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
PE20150218A1 true PE20150218A1 (es) 2015-02-14

Family

ID=50288170

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014001093A PE20150218A1 (es) 2013-07-23 2014-07-10 Nuevos derivados fosfatos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen

Country Status (48)

Country Link
US (3) US9115159B2 (es)
EP (1) EP2829545B1 (es)
JP (1) JP5894638B2 (es)
KR (2) KR101713103B1 (es)
CN (1) CN104341451B (es)
AP (1) AP2014007773A0 (es)
AR (1) AR097008A1 (es)
AU (1) AU2014203808B2 (es)
BR (1) BR102014017997B1 (es)
CA (1) CA2856886C (es)
CL (1) CL2014001865A1 (es)
CR (1) CR20140336A (es)
CU (1) CU24316B1 (es)
CY (1) CY1117834T1 (es)
DK (1) DK2829545T3 (es)
DO (1) DOP2014000163A (es)
EA (1) EA027444B1 (es)
EC (1) ECSP14008757A (es)
ES (1) ES2593417T3 (es)
FR (1) FR3008979B1 (es)
GE (1) GEP201706704B (es)
HK (2) HK1201536A1 (es)
HR (1) HRP20161202T8 (es)
HU (1) HUE029616T2 (es)
IL (1) IL233580B (es)
JO (1) JO3160B1 (es)
MA (1) MA37213B1 (es)
MD (1) MD4551C1 (es)
ME (1) ME02641B (es)
MX (1) MX351467B (es)
MY (1) MY173258A (es)
NI (1) NI201400080A (es)
PE (1) PE20150218A1 (es)
PH (1) PH12014000194A1 (es)
PL (1) PL2829545T3 (es)
PT (1) PT2829545T (es)
RS (1) RS55098B1 (es)
RU (1) RU2617682C2 (es)
SA (1) SA114350669B1 (es)
SG (1) SG10201403939WA (es)
SI (1) SI2829545T1 (es)
SV (1) SV2014004771A (es)
TN (1) TN2014000301A1 (es)
TW (1) TWI527824B (es)
UA (1) UA119738C2 (es)
UY (1) UY35661A (es)
WO (1) WO2015011399A1 (es)
ZA (1) ZA201405418B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
FR3008977A1 (fr) * 2013-07-23 2015-01-30 Servier Lab Nouveaux derives d'isoindoline ou d'isoquinoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3008976A1 (fr) * 2013-07-23 2015-01-30 Servier Lab "nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent"
UY37316A (es) * 2016-07-07 2018-01-31 Servier Lab Dispersión sólida farmacéutica de un inhibidor de bcl-2, composiciones farmacéuticas de ésta, y usos para el tratamiento de cáncer
UA125138C2 (uk) * 2016-07-22 2022-01-19 Ле Лаборатуар Сервьє Комбінація інгібітора bcl-2 та інгібітора mcl-1, їхнє застосування і фармацевтичні композиції
AU2017300738A1 (en) 2016-07-22 2019-02-07 Les Laboratoires Servier Combination of a BCL-2 inhibitor and a MCL-1 inhibitor, uses and pharmaceutical compositions thereof
WO2018158225A1 (en) 2017-02-28 2018-09-07 Les Laboratoires Servier Combination of a bcl-2 inhibitor and a mdm2 inhibitor, uses and pharmaceutical compositions thereof
EA039621B1 (ru) * 2017-06-09 2022-02-17 Ле Лаборатуар Сервье Комбинация bcl-2 ингибитора и mcl-1 ингибитора, их применения и фармацевтические композиции
AR112440A1 (es) * 2017-07-06 2019-10-30 Servier Lab Forma cristalina de un inhibidor de bcl-2, un proceso para su preparación y composiciones farmacéuticas que la contienen
FR3072679B1 (fr) * 2017-10-25 2020-10-30 Servier Lab Nouveaux derives macrocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
MX2022001863A (es) 2019-08-12 2022-05-30 Deciphera Pharmaceuticals Llc Metodos para tratar los tumores del estroma gastrointestinal.
WO2021030405A1 (en) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
CN110606860B (zh) * 2019-09-29 2021-12-10 上海勋和医药科技有限公司 一种吡啶磺酰胺磷酸酯类化合物、其制备方法及其用途
RS65058B1 (sr) 2019-12-30 2024-02-29 Deciphera Pharmaceuticals Llc Formulacije inhibitora amorfne kinaze i postupci njihove primene
BR112022013169A2 (pt) 2019-12-30 2022-09-13 Deciphera Pharmaceuticals Llc Composições de 1-(4-bromo-5-(1-etil-7-(metilamino)-2-oxo-1,2-diidro-1,6-naftiridin-3-il)-2-fluorofeil)-3-fenilurea
BR112023017344A2 (pt) * 2021-03-12 2023-09-26 Eil Therapeutics Inc Compostos que têm tetra-hidroindolizina-1-carboxamida como inibidores de bcl-2
WO2023057394A1 (en) 2021-10-04 2023-04-13 Forx Therapeutics Ag N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer
WO2023225359A1 (en) 2022-05-20 2023-11-23 Novartis Ag Antibody-drug conjugates of antineoplastic compounds and methods of use thereof
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1501514B1 (en) * 2002-05-03 2012-12-19 Exelixis, Inc. Protein kinase modulators and methods of use
US20050124614A1 (en) * 2002-07-03 2005-06-09 Axys Pharmaceuticals, Inc. 3,4-Dihydroisoquinolin-1-one derivatives as inducers of apoptosis
GB0224557D0 (en) * 2002-10-22 2002-11-27 Glaxo Group Ltd Novel compounds
JP2009524589A (ja) * 2005-12-22 2009-07-02 ワイス 置換されたイソキノリン−1,3(2h,4h)−ジオン、1−チオキソ−1,4−ジヒドロ−2h−イソキノリン−3−オン誘導体、および1,4−ジヒドロ−3(2h)−イソキノロン、ならびにキナーゼインヒビターとしてのそれらの使用
US7902218B2 (en) * 2006-12-12 2011-03-08 Bristol-Myers Squibb Company Substituted tetrahydroisoquinolines as β-secretase inhibitors
EP2134684B1 (en) * 2007-04-16 2017-08-02 AbbVie Inc. 7-substituted indole as mcl-1 inhibitors
KR101352709B1 (ko) 2007-05-22 2014-01-16 아스테라스 세이야쿠 가부시키가이샤 1위 치환 테트라히드로이소퀴놀린 화합물
CA2714414A1 (en) * 2008-02-13 2009-08-20 Cgi Pharmaceuticals, Inc. Certain substituted amides, method of making, and method of use thereof
EP2373163B1 (en) * 2008-12-19 2015-06-10 Genentech, Inc. Heterocyclic compounds and methods of use
TWI520960B (zh) * 2010-05-26 2016-02-11 艾伯維有限公司 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑
US20120301080A1 (en) 2011-05-23 2012-11-29 Senko Advanced Components, Inc. True one piece housing fiber optic adapter
AU2012355613A1 (en) 2011-12-23 2014-07-17 Novartis Ag Compounds for inhibiting the interaction of BCL2 with binding partners
JP2015503516A (ja) 2011-12-23 2015-02-02 ノバルティス アーゲー Bcl2と結合相手の相互作用を阻害するための化合物
EP2794592A1 (en) 2011-12-23 2014-10-29 Novartis AG Compounds for inhibiting the interaction of bcl2 with binding partners
EP2794591A1 (en) 2011-12-23 2014-10-29 Novartis AG Compounds for inhibiting the interaction of bcl2 with binding partners
JP2015503517A (ja) 2011-12-23 2015-02-02 ノバルティス アーゲー Bcl2と結合相手の相互作用を阻害するための化合物
CN103177906A (zh) 2011-12-26 2013-06-26 西门子公司 用于中压开关设备的断路器
ITPR20110103A1 (it) 2011-12-27 2013-06-28 G E A F S R L Metodo e apparato per la sterilizzazione di una soluzione liquida mediante radio frequenza
US9114953B2 (en) 2011-12-29 2015-08-25 Inventio Ag Emergency operation of elevators based on an indicated emergency condition
FR2986002B1 (fr) * 2012-01-24 2014-02-21 Servier Lab Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE212013000059U1 (de) 2012-01-24 2014-09-11 Danfoss Power Electronics A/S Entfeuchter

Also Published As

Publication number Publication date
EA027444B1 (ru) 2017-07-31
DOP2014000163A (es) 2015-01-15
DK2829545T3 (en) 2016-09-19
CA2856886A1 (fr) 2015-01-23
SG10201403939WA (en) 2015-02-27
AP2014007773A0 (en) 2014-07-31
SI2829545T1 (sl) 2016-10-28
ECSP14008757A (es) 2016-01-29
PT2829545T (pt) 2016-07-13
MD4551B1 (ro) 2018-02-28
MX2014008866A (es) 2015-07-21
AU2014203808B2 (en) 2018-09-20
EA201400754A2 (ru) 2014-12-30
NI201400080A (es) 2014-10-24
MY173258A (en) 2020-01-09
CU20140095A7 (es) 2016-02-29
AR097008A1 (es) 2016-02-10
HK1201536A1 (zh) 2015-09-04
MX351467B (es) 2017-10-17
MD20140073A2 (en) 2015-01-31
EP2829545B1 (fr) 2016-06-22
MA37213A1 (fr) 2016-06-30
ME02641B (me) 2017-06-20
TWI527824B (zh) 2016-04-01
US9115159B2 (en) 2015-08-25
BR102014017997B1 (pt) 2020-05-19
US20150313923A1 (en) 2015-11-05
KR101713103B1 (ko) 2017-03-07
PH12014000194B1 (en) 2015-06-29
CU24316B1 (es) 2018-02-08
GEP201706704B (en) 2017-07-25
CA2856886C (fr) 2016-08-02
CN104341451B (zh) 2018-04-03
UY35661A (es) 2015-02-27
SV2014004771A (es) 2015-01-28
HUE029616T2 (en) 2017-03-28
RU2014130129A (ru) 2016-02-10
CN104341451A (zh) 2015-02-11
SA114350669B1 (ar) 2016-04-11
BR102014017997A2 (pt) 2015-11-17
PH12014000194A1 (en) 2015-06-29
PL2829545T3 (pl) 2016-12-30
TW201504254A (zh) 2015-02-01
KR20150011785A (ko) 2015-02-02
CR20140336A (es) 2015-10-07
TN2014000301A1 (fr) 2015-12-21
US20150031648A1 (en) 2015-01-29
WO2015011399A1 (fr) 2015-01-29
ES2593417T3 (es) 2016-12-09
US20170143746A1 (en) 2017-05-25
KR20170001694A (ko) 2017-01-04
CL2014001865A1 (es) 2015-06-26
IL233580B (en) 2020-03-31
HRP20161202T8 (hr) 2016-12-30
UA119738C2 (uk) 2019-08-12
FR3008979B1 (fr) 2015-07-24
FR3008979A1 (fr) 2015-01-30
ZA201405418B (en) 2020-02-26
HK1204623A1 (en) 2015-11-27
JO3160B1 (ar) 2017-09-20
US9597341B2 (en) 2017-03-21
MA37213B1 (fr) 2017-03-31
NZ627178A (en) 2016-01-29
CY1117834T1 (el) 2017-05-17
EA201400754A3 (ru) 2015-03-31
AU2014203808A1 (en) 2015-02-12
EP2829545A1 (fr) 2015-01-28
IL233580A0 (en) 2014-11-02
JP5894638B2 (ja) 2016-03-30
JP2015028017A (ja) 2015-02-12
MD4551C1 (ro) 2018-09-30
RU2617682C2 (ru) 2017-04-26
HRP20161202T1 (hr) 2016-11-04
RS55098B1 (sr) 2016-12-30

Similar Documents

Publication Publication Date Title
PE20150218A1 (es) Nuevos derivados fosfatos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
PE20150399A1 (es) Nuevos derivados de pirrol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
PE20211411A1 (es) Compuestos de anillo fusionado
PE20171307A1 (es) Compuestos de triazolopirimidina y usos de los mismos
PE20171240A1 (es) Derivados de 4h-pirrol[3,2-c]piridin-4-ona
CY1120248T1 (el) Ενωσεις ιμιδαζο[4,5-c]κινολιν-2-ονης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου
PE20160240A1 (es) Nuevos derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
PE20160875A1 (es) Compuestos de biaril-amida como inhibidores de cinasa
DOP2018000187A (es) Derivados de pirazolo[1,5-a]pirazin-4-ilo
AR104025A1 (es) Carbamatos de piperazina como moduladores de magl y/o abhd6, procesos para su preparación y composiciones farmacéuticas
PE20201448A1 (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
PE20161066A1 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
PE20121815A1 (es) Compuestos de pirrolo-pirimidina como inhibidores de cdk4/6
AR103252A1 (es) Compuestos de quinazolina
GT201400301A (es) 7h-pirrolo [2,3-d] pirimidinas-4- ( aminho-substituidas) novedosas como inhibidores de lrrk2
AR112216A1 (es) Derivados de azaquinolina
PE20170127A1 (es) Indazol-3-carboxamidas 5-sustituidas y preparacion y uso de las mismas
PE20190656A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
PE20090493A1 (es) DERIVADOS DE LA 6-CICLOAMINO-3-(PIRIDAZIN-4-IL)IMIDAZO[1,2-b]-PIRIDAZINA, SU PREPARACION Y SU APLICACION EN TERAPEUTICA
EA201200174A1 (ru) Производные оксазина и их применение в качестве ингибиторов bace для лечения неврологических нарушений
PE20142376A1 (es) Fluormetil-5,6-dihidro-4h-[1,3]oxazinas
PE20181288A1 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer
EA201490491A1 (ru) Производные 2-амино-4-(пиридин-2-ил)-5,6-дигидро-4h-1,3-оксазинов и их использование в качестве ингибиторов bace-1 и/или bace-2
EA201200176A1 (ru) Производные оксазина и их применение для лечения неврологических нарушений
PE20120534A1 (es) PIRIMIDINAS FUSIONADAS COMO INHIBIDORES DE Akt

Legal Events

Date Code Title Description
FG Grant, registration